![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Accepts Tercica's Increlex NDA With Priority Review
FDA Accepts Tercica's Increlex NDA With Priority Review
The FDA has accepted for filing and granted priority review of Tercica's new drug application (NDA) for Increlex, or recombinant human insulin-like growth factor-1 (rhIGF-1).
The company is seeking approval to market Increlex (mecasermin [rDNA origin] injection) for the long-term treatment of short stature caused by a severe form of primary IGF-1 deficiency (Primary IGFD).
Based on the priority-review designation, the FDA has six months from the submission date, by Aug. 31, to take action on the NDA filing.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct